Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRONNASDAQ:EOLSNASDAQ:GNFTNYSE:NUVB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRONCronos Group$1.72$1.87$1.60▼$3.14$662.90M1.021.47 million shs1.30 million shsEOLSEvolus$10.23-0.4%$12.78$8.67▼$17.82$650.50M0.97650,918 shs815,872 shsGNFTGenfit$3.68+6.4%$3.57$2.55▼$6.42$183.99M1.2214,470 shs7,562 shsNUVBNuvation Bio$2.03+0.2%$2.00$1.54▼$3.97$685.83M1.472.04 million shs3.19 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRONCronos Group0.00%+6.17%-8.99%-13.13%-29.51%EOLSEvolus-0.39%+9.29%-22.50%+1.59%-13.96%GNFTGenfit+6.36%+9.52%+4.69%+6.36%+4.84%NUVBNuvation Bio0.00%+22.36%-5.15%-22.12%-29.69%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRONCronos Group1.5759 of 5 stars2.05.00.00.02.10.01.3EOLSEvolus3.5092 of 5 stars3.51.00.03.51.82.50.6GNFTGenfit1.556 of 5 stars3.53.00.00.02.00.00.0NUVBNuvation Bio2.4722 of 5 stars3.60.00.00.03.53.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRONCronos Group 0.00N/A$3.50103.49% UpsideEOLSEvolus 3.00Buy$24.67141.12% UpsideGNFTGenfit 3.00Buy$13.00253.26% UpsideNUVBNuvation Bio 3.25Buy$8.75332.10% UpsideCurrent Analyst Ratings BreakdownLatest GNFT, NUVB, CRON, and EOLS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/9/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/27/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.003/12/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.003/11/2025NUVBNuvation BioJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/10/2025NUVBNuvation BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$11.00 ➝ $10.003/5/2025EOLSEvolusNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.003/5/2025EOLSEvolusBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$22.00 ➝ $25.003/3/2025NUVBNuvation BioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$5.002/14/2025EOLSEvolusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.00(Data available from 4/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRONCronos Group$117.62M5.64N/AN/A$2.87 per share0.60EOLSEvolus$266.27M2.44N/AN/A($0.36) per share-28.42GNFTGenfit$76.06M2.42N/AN/A$1.48 per share2.49NUVBNuvation Bio$7.87M87.11N/AN/A$2.76 per share0.73Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRONCronos Group-$73.96M$0.10N/A57.331.74-42.65%-2.56%-2.47%5/8/2025 (Estimated)EOLSEvolus-$61.69M-$0.81N/AN/AN/A-22.33%-847.60%-22.15%5/6/2025 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A4/24/2025 (Estimated)NUVBNuvation Bio-$75.80M-$2.26N/AN/AN/AN/A-21.89%-17.86%5/13/2025 (Estimated)Latest GNFT, NUVB, CRON, and EOLS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NUVBNuvation Bio-$0.16N/AN/AN/A$0.42 millionN/A5/6/2025Q1 2025EOLSEvolus-$0.04N/AN/AN/A$73.06 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRONCronos GroupN/AN/AN/AN/AN/AEOLSEvolusN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ANUVBNuvation BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRONCronos GroupN/A24.2423.05EOLSEvolus20.582.472.23GNFTGenfit0.613.743.74NUVBNuvation BioN/A9.579.57Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRONCronos Group8.71%EOLSEvolus90.69%GNFTGenfit2.24%NUVBNuvation Bio61.67%Insider OwnershipCompanyInsider OwnershipCRONCronos Group6.90%EOLSEvolus6.10%GNFTGenfit4.20%NUVBNuvation Bio5.07%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRONCronos Group450385.41 million356.14 millionOptionableEOLSEvolus17063.59 million59.46 millionOptionableGNFTGenfit12050.00 million47.90 millionNot OptionableNUVBNuvation Bio60338.68 million319.50 millionOptionableGNFT, NUVB, CRON, and EOLS HeadlinesRecent News About These CompaniesNuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Fmr LLCApril 16 at 3:55 AM | marketbeat.comIs Nuvation Bio Inc. (NUVB) the Top Healthcare Stock to Buy According to Billionaire David Einhorn?April 14 at 6:13 AM | msn.comNuvation Bio Inc. (NYSE:NUVB) Shares Acquired by Vanguard Group Inc.April 14 at 3:21 AM | marketbeat.comInsider Buying: Nuvation Bio Inc. (NYSE:NUVB) CEO Purchases 200,000 Shares of StockApril 11, 2025 | marketbeat.comDavid Hung Acquires 300,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) StockApril 10, 2025 | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) CEO David Hung Acquires 200,000 SharesApril 10, 2025 | insidertrades.comTuesday’s Insider Activity: Key Buys and Sells in US StocksApril 9, 2025 | investing.comNuvation Bio Inc. (NUVB): Among Stocks Under $10 that Will TripleApril 9, 2025 | msn.comNuvation Bio (NYSE:NUVB) Reaches New 1-Year Low - What's Next?April 9, 2025 | marketbeat.comDavid Hung Buys 300,000 Shares of Nuvation Bio Inc. (NYSE:NUVB) StockApril 9, 2025 | insidertrades.comNuvation Bio (NYSE:NUVB) Stock Price Up 5.4% - Here's What HappenedApril 4, 2025 | marketbeat.comNuvation Bio to Present at the Jones Healthcare and Technology Innovation ConferenceApril 2, 2025 | businesswire.comNuvation Bio (NYSE:NUVB) Sets New 12-Month Low - Should You Sell?April 1, 2025 | marketbeat.comNuvation Bio (NYSE:NUVB) Receives "Outperform" Rating from WedbushMarch 28, 2025 | marketbeat.comNuvation Bio Inc. (NYSE:NUVB) Stock Position Boosted by Charles Schwab Investment Management Inc.March 26, 2025 | marketbeat.comInsider Stock Buying Reaches US$720.1k On Nuvation BioMarch 25, 2025 | uk.finance.yahoo.comNuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025March 25, 2025 | businesswire.comStock Traders Buy High Volume of Nuvation Bio Put Options (NYSE:NUVB)March 21, 2025 | marketbeat.comIs Nuvation Bio Inc. (NYSE:NUVB) the Most Oversold Penny Stocks to Buy According to Analysts?March 17, 2025 | msn.comJones Trading Initiates Coverage of Nuvation Bio (NUVB) with Buy RecommendationMarch 12, 2025 | msn.comNuvation Bio initiated with a Buy at JonesResearchMarch 11, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Micron Stock Will Retest All-Time Highs This YearBy Thomas Hughes | March 21, 2025View Micron Stock Will Retest All-Time Highs This YearMicron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesBy Thomas Hughes | April 11, 2025View Micron Tumbles on Tariff Threat: Risk/Reward Outlook ImprovesGNFT, NUVB, CRON, and EOLS Company DescriptionsCronos Group NASDAQ:CRON$1.72 0.00 (0.00%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$1.72 0.00 (-0.29%) As of 04/15/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.Evolus NASDAQ:EOLS$10.23 -0.04 (-0.39%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$9.93 -0.31 (-2.98%) As of 04:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.Genfit NASDAQ:GNFT$3.67 +0.21 (+6.18%) As of 04/15/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.Nuvation Bio NYSE:NUVB$2.02 +0.01 (+0.25%) Closing price 04/15/2025 03:59 PM EasternExtended Trading$2.02 0.00 (-0.05%) As of 04:18 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas CrowdStrike Stock is a Buy as Cyberthreat Environment Expands Congress! Who Traded What During the Tariff-Induced Meltdown Beware of BigBear.ai: Insiders Are Selling—Should You? NATO Deal Sparks 4% Jump in Palantir Stock—What’s Next? Microsoft: A Blend of Growth and Value Amid Tariff Concerns Why NVIDIA Stock Could Soar Despite Wall Street Downgrades Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold Don’t Fear, New Highs for Fastenal Will Soon Be Here Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
